Denosumab for Treatment of Hypercalcemia of Malignancy
Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Rajul K. Jain(Amgen (United States)), Diégo Tosi(Institut de Recherche en Cancérologie de Montpellier), Rasim Gucalp(Montefiore Medical Center), Waldemar Misiorowski(Postgraduate School of Molecular Medicine), Ilya Glezerman(Memorial Sloan Kettering Cancer Center), Giuseppe Tonini(Campus Bio Medico University Hospital), Wendy Ying(Allogene Therapeutics (United States)), Karl Insogna(Yale University), Sophie Leboulleux(Geneva College), Paul Zorsky(Peninsula Regional Medical Center), Alberto Bessudo(California Cancer Associates for Research and Excellence), Bennett W. Yu(Moffitt Cancer Center), Ada Braun(National Cancer Centre Japan), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges)
Cited by 200
Related Papers
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863